The abstract is read at the publisher; the summary is JClub's.
In resectable non-small cell lung cancer, major pathologic response is linked to spatial enrichment of T- and B-cell activation pathways and CD8+ T-cell infiltration, with an MPR rate of 37.5%.
- Why it matters: Neoadjuvant chemoimmunotherapy improves outcomes, but the spatial immune features that track with response and could guide adjuvant treatment selection are not well defined.
- What they did: In a single-arm phase II trial (NCT05383716), 22 patients had digital spatial profiling of resected tumors and paired draining lymph nodes, with validation using additional tumor samples.
- The result: Two MPR immune phenotypes emerged (myeloid-enriched and lymphoid-enriched); the lymphoid-enriched subtype associated with improved response and survival, and an 18-gene lymphoid-enriched signature was developed for potential biomarker use.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.